Metraipolis › archive › dc_8cd303ea93eb

Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China — Europe PMC PMID:41190033

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41190033
DOI: 10.3389/fphar.2025.1651463
License (as archived): solo-consultazione
Archived: 2026-11-09T05:06:03.870Z
SHA-256 of the archived text: 848a8e53ff406de1dbb8786d6ca91e005502d980d8802e448a633ffd99052094
Stable URL of this page: https://metraipolis.com/documento/dc_8cd303ea93eb

How to cite

Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China — Europe PMC PMID:41190033 — Europe PMC (en), https://europepmc.org/article/MED/41190033 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8cd303ea93eb (Metraipolis archive dc_8cd303ea93eb, sha256 848a8e53ff406de1dbb8786d6ca91e005502d980d8802e448a633ffd99052094)

BibTeX

@misc{dc8cd303ea93eb,
  title = {Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China — Europe PMC PMID:41190033},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41190033},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8cd303ea93eb; sha256 848a8e53ff406de1dbb8786d6ca91e005502d980d8802e448a633ffd99052094},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41190033. Agents can read the archived copy with the MCP tool read_document.